Too soon to declare victory: “the end of the the AIDS epidemic” may be within reach, but . . . – “Leave No One Behind” . . . “Protect and Uphold Human Rights” . . . “Decriminalize HIV . . .” “Ensure Treatment Access Now” . . . “Fully Finance a Comprehensive HIV Response” . . . These may sound like no-brainers to anyone responding to HIV anywhere, but even as talk of victory over the pandemic grows more optimistic, these are some of the necessary steps to that goal that still aren’t happening. ICASO is circulating Ten Civil Society Priorities, with a reminder that they are necessary to ending AIDS.
View on Private Sector: Pharma shift won’t help poorest – This explains why pharmaceutical company GlaxoSmithKline’s announcement that it would stop filing patents in the world’s poorest countries strikes global health equity advocates as more of an acknowledgement of a problem than a solution.
DNDi and Pharco Pharmaceuticals to test affordable hepatitis C regimen – And here’s a different way to address treatment costs that turn life-saving medicines into luxuries.
How could I have gotten this? Reflections on MDR-TB from a Nigerian student – “If I had been in Nigeria and diagnosed with MDR-TB, I would be dead by now, because we don’t have what it takes to take care of this disease.” As it is, Tanwa, a Nigerian-born nursing student living in the U.S. and undergoing treatment for multidrug-resistant tuberculosis, details the effects of a harsh regimen, isolation, stigma and depression in this RESULTS interview, underscoring why U.S. investments in TB research are critical.
Global threats are local threats – All of the cases mapped here are travel-related, but they set the stage for the approaching mosquito-breeding season and the risks of local transmission it will bring, even as a growing body of knowledge about health threats posed by vector-borne virus also adds to concerns. This graphic and this look at why the US is vulnerable to the spread of the virus are a reminder that without capacities to deliver care, track illness, monitor developments and respond rapidly everywhere, apparently obscure infectious diseases can transform into overwhelming problems anywhere.